Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Medivation

Share:
Related MDVN
$45 Billion Thursday For M&A Shows There Are Still Plenty Of Buyers Out There
Here's What Medivation Said In Its Rejection Letter To Sanofi
The Week In Review: Is Apple Still A Growth Enterprise? Is America? (Investor's Business Daily)

In a report published Monday, Jefferies & Company reiterated its Buy rating on Medivation (NASDAQ: MDVN), and slightly raised its price target from $61.00 to $62.00.

Jefferies noted, “Following the strong Xtandi beat on 2 wks of sales in Sep and guidance for 4Q12-1Q13 announced by Astellas 2 wks ago, MDVN provided incremental commentary during its Q3 earnings on inventory, 3rd party Rx data, ongoing Xtandi clinical trials and PnL nuts & bolts. We continue to believe in a strong Xtandi launch and have ramped up our initial sales trajectory, offset by higher spend to support a new PT of $62.”

Medivation closed on Friday at $45.70.

Latest Ratings for MDVN

DateFirmActionFromTo
Apr 2016JP MorganTerminatesOverweight
Apr 2016BMO CapitalInitiates Coverage onMarket Perform
Apr 2016SunTrust Robinson HumphreyInitiates Coverage onBuy

View More Analyst Ratings for MDVN
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (MDVN)

View Comments and Join the Discussion!